BioCentury
ARTICLE | Finance

Navigating Third Rock's Maze

How genetic modifier play Maze plans to deploy $191M financing

February 28, 2019 3:00 PM UTC

After Third Rock Ventures incubated Maze Therapeutics for two years, the company debuted Thursday with $191 million and plans to generate data for its three genetic modifier programs in the next 3-5 years.

Third Rock and Arch Venture Partners led the financing, with participation from GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments and other undisclosed investors. Third Rock's Charles Homcy told BioCentury the financing represented multiple rounds but did not provide details...